Takeda joins Novartis and Merck in $45M funding for Koneksa Health

Takeda Ventures has joined Novartis and Merck in backing Koneksa Health, which bills itself as a digital biomarker company. Koneksa's platform stands to benefit from the renewed interest the COVID-19 pandemic brought to remote monitoring of clinical trials, since the technology is designed to collect patient data remotely and analyze details in real time.